Tapinarof, a Novel Topical Therapeutic Aryl Hydrocarbon Receptor Agonist, Suppresses Atopic Dermatitis-like Skin Inflammation in Mice

DOI Web Site 36 References
  • Urashima Toshiki
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Katsuda Yoshiaki
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Yoshiuchi Hiromi
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Ebihara Shin
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Shinozaki Yuichi
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Kato Tomoko
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Shimazaki Taishi
    Toxicology Research Laboratories, Yokohama Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Yasui Yuzo
    Toxicology Research Laboratories, Yokohama Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Mera Yasuko
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.
  • Konishi Noriko
    Biological/Pharmacological Research Laboratories, Takatsuki Research Center, Central Pharmaceutical Research Institute, Japan Tobacco Inc.

Description

<p>Tapinarof is a non-steroidal, small molecule aryl hydrocarbon receptor (AhR) agonist that is being developed for the treatment of atopic dermatitis (AD). AD is a chronic inflammatory skin disease mediated by type 2 helper T (Th2) cells, characterized by impaired epidermal differentiation and skin barrier function. Tapinarof has been reported to regulate target gene expression through activation of AhR, improve skin barrier function, and exhibit an antioxidant effect. In this study, we investigated the pharmacological properties of tapinarof and its efficacy in mice with AD-like skin inflammation induced by 2, 4-dinitrofluorobenzene (DNFB). Tapinarof induced the mRNA expression of CYP1A1, an indicator of AhR activation, induced the mRNA expression of NAD(P)H: quinone oxidoreductase (NQO1), an antioxidant enzyme in human peripheral blood mononuclear cells (PBMCs) stimulated with T-cell activators. It also suppressed the production of interleukin (IL)-4, a Th2 cytokine. In mice with AD-like dermatitis, topical administration of tapinarof promoted the expression of Cyp1a1 and Nqo1 in the skin. It suppressed IL-4 production, the ear swelling, and histopathological changes. Tapinarof also suppressed an increase in transepidermal water loss (TEWL), an indicator of skin barrier function. These results indicate that tapinarof suppresses AD-like skin dermatitis and suggest that a variety of pharmacological actions, including an antioxidant effect, inhibition of Th2 cytokine, and improvement in barrier function, are involved.</p>

Journal

  • BPB Reports

    BPB Reports 7 (4), 123-131, 2024

    The Pharmaceutical Society of Japan

References(36)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top